We randomised 120 patients who were undergoing either primary total hip or knee arthroplasty to receive either ferrous sulphate or a placebo for three weeks after surgery. The level of haemoglobin and absolute reticulocyte count were measured at one and five days, and three and six weeks after operation. Ninety-nine patients (ferrous sulphate 50, placebo 49) completed the study. The two groups differed only in the treatment administered.
We randomised 120 patients who were undergoing either primary total hip or knee arthroplasty to receive either ferrous sulphate or a placebo for three weeks after surgery. The level of haemoglobin and absolute reticulocyte count were measured at one and five days, and three and six weeks after operation. Ninety-nine patients (ferrous sulphate 50, placebo 49) completed the study. The two groups differed only in the treatment administered.
Recovery of level of haemoglobin was similar at five days and three weeks and returned to 85% of the pre-operative level, irrespective of the treatment group. A small, albeit greater recovery in the level of haemoglobin was identified at six weeks in the ferrous sulphate group in both men (ferrous sulphate 5%, placebo 1.5%) and women (ferrous sulphate 6%, placebo 3%). The clinical significance of this is questionable and may be outweighed by the high incidence of reported side effects of oral iron and the cost of the medication. Administration of iron supplements after elective total hip or total knee arthroplasty does not appear to be worthwhile.
Anaemia is common after joint replacement surgery. 1 Patients with significant anaemia, or those who are haemodynamically unstable may require blood transfusion. 2 The hazards associated with homologous blood transfusion are well known and include incompatibility, infection, immunosuppression, and alloimmunisation. 3, 4 Transfusions are expensive and orthopaedic units should have guidelines to reduce unnecessary risks to the patient. 5 The cardiorespiratory consequences of moderate anaemia may be significant in limiting the mobility of patients after lower-limb arthroplasty. 6 Such patients may benefit from a quick return of the level of haemoglobin to its preoperative value.
The appreciable risks of transfusion have resulted in surgeons using alternative methods including autologous transfusion, intra-operative blood salvage and the administration of aprotonin, desmopressin and erythropoetin. 7, 8 Oral iron therapy has also frequently been used although its use is not without hazard since side-effects such as constipation, gastric irritation and diarrhoea have been reported in up to 25% of patients. 9 Major surgery also induces a state of hypoferraemia and temporary changes in iron metabolism which may make iron supplementation ineffective. 10, 11 Previous studies 12, 13 have concluded that the use of ferrous sulphate post-operatively is not beneficial. However, either the numbers involved were small which made statistical conclusions doubtful or the study covered only a short post-operative period. Our aim therefore was to determine whether or not supplementary oral iron therapy in patients after elective, primary lower limb arthroplasty resulted in an accelerated recovery of the level of haemoglobin.
Patients and Methods
The study protocol was approved by the Leicestershire Research Ethics Committee before the patients were recruited. Consecutive patients who were undergoing elective primary total hip or knee arthroplasty were interviewed at the pre-assessment clinic. Each patient was given an information sheet which detailed the purpose of the study. In addition to routine pre-operative assessment, a reticulocyte count was done and plasma viscosity and the levels of C-reactive protein (CRP) and serum ferritin were measured. All patients, regardless of their participation in the trial, were advised to stop taking antiplatelet drugs, including non-steroidal anti-inflammatory drugs (NSAIDS) before surgery. The decision as to whether or not patients participated was determined when they returned two weeks later for surgery. All the surgical procedures were performed or overseen by five consultant surgeons. Patients were excluded pre-operatively for the reasons shown in Table I . Those who satisfied the entry criteria were randomised to receive either ferrous sulphate (200 mg, containing 65 mg of elemental iron) or a placebo, orally, three times daily. Treatment began on the second post-operative day and continued for three weeks. The entire number of tablets remaining at the time of discharge was supplied to the patient in order to complete the course at home. The patients also took thromboprophylaxis medication with enoxaparin 40 mg once daily on the first post-operative day which was then changed to aspirin 75 mg once daily on the fifth post-operative day. This was continued for six weeks in accordance with departmental guidelines. Post-operative NSAIDS were prescribed according to the preference of either the surgeon or the anaesthetist.
Patients were excluded if they were received a transfusion more than 72 hours after surgery. Other exclusion criteria included the development of acute medical complications, bleeding from a distant site such as the gastrointestinal tract, allergy to the medication and non-compliance. Full blood counts were taken on the first and fifth postoperative days and at three and six weeks after surgery. The absolute reticulocyte count was recorded on the fifth day and at three and six weeks. The level of haemoglobin between the two groups was compared at each point. This method was limited in that it did not take account of perioperative transfusions, or the re-equilibration of plasma volume. 13 We, therefore, also analysed the percentage recovery of haemoglobin compared with the pre-operative level. Compliance was monitored by reviewing the inpatient prescription chart and at a home visit three weeks following surgery. Statistical analysis. The study was designed to detect a difference in the mean haemoglobin level of ≥ 0.5 g/dl between the two groups and with a power of 90%. After fulfilment of the entry criteria, the hospital research pharmacist was contacted in order to assign the treatment group. Randomisation was performed using scientific tables. The numbers were chosen from rows of ten numbers in which even numbers were allocated treatment with ferrous sulphate and odd numbers were allocated a placebo. Both the surgeons and the patients were blinded to the treatment group. Comparability of the treatment groups was assessed for categorical variables using the chi-squared test. Continuous variables were assessed using Student's t-test. We considered a p value < 0.05 to be significant. All p values were two-sided and all analyses were performed using Microsoft Excel (Microsoft, Seattle, Washington).
Results
Between June 11 and March 31, 2003, 334 patients were screened for inclusion in the study of whom 207 were ineligible for the following reasons: low haemoglobin (46), low platelet count (6), raised CRP (28), a past history of cancer (16) , abnormal renal function (15), low serum ferritin (16), current administration of iron supplements (21), and unwillingness to participate (84). Some were ineligible for more than one reason. Seven patients were ineligible for entry into the study after surgery for the following reasons: chest infection (1), confusion (4) and renal dysfunction (2). We randomised 120 patients to receive either ferrous sulphate or a placebo although 21 (ferrous sulphate 11, placebo 10) were excluded after randomisation for the following reasons: blood transfusion > 72 hours after surgery (ferrous sulphate 3, placebo 1), periprosthetic fracture which required revision surgery (placebo 1), bowel obstruction leading to a laparotomy (ferrous sulphate 1) and noncompliance (15) . The reasons given for non-compliance included constipation (ferrous sulphate 4, placebo 6), diarrhoea (ferrous sulphate 1, placebo 1) and difficulty in swallowing the medication (ferrous sulphate 2, placebo 1). The remaining 99 patients formed the study group of whom 50 received ferrous sulphate and 49 a placebo. All were Caucasian. The two groups were comparable for gender and age, number of hip or knee arthroplasties, and the number of patients who were transfused (Table II) . The baseline level of haemoglobin was similar in the two groups for both men and women. No significant differences in the actual haemoglobin level were noted between the two groups for either men or women during the period of six weeks (Table III) .
A decrease of approximately 30% in the haemoglobin level was seen immediately after surgery in both men and women ( Fig. 1) . At the end of the period of treatment, three weeks after surgery, a recovery of the level of haemoglobin to approximately 85% of the pre-operative value was observed in both the treatment and the placebo groups. This recovery was similar in both men (ferrous sulphate 86.6%, placebo 85.1%, p = 0.45) and women (ferrous sulphate 88.5%, placebo 86.7%, p = 0.35). A much smaller but significant increase was noted three weeks later in both the male and the female ferrous sulphate groups. This equated to a further recovery in the level of haemoglobin of 6% (ferrous sulphate) compared with 3% (p < 0.01) in women and 5% (ferrous sulphate) compared with 1.5% (p < 0.05) in men. The absolute reticulocyte counts were analysed for each group (Fig. 2) . No significant difference was noted between the treatment and the placebo groups. How- Absolute reticulocyte count measured over the six-week period (FS, ferrous sulphate; P, placebo). ever, there was a highly significant increase in the absolute reticulocyte count on the fifth day and at three weeks compared with the pre-operative value for both groups. The value at six weeks was comparable with the pre-operative value (Table IV) .
Discussion
The development of acute anaemia after total hip or knee arthroplasty is common and may be defined as a reduction in the oxygen-transporting capacity of blood, usually because of a reduction in the total circulating red cell mass to below normal levels. 1, 14 The best treatment for asymptomatic, haemodynamically-stable patients is unclear. This problem has assumed greater importance since the introduction of recommendations for transfusion in order to limit blood transfusion and its associated complications. [3] [4] [5] We currently only transfuse patients with a haemoglobin level of < 8 g/dl, or symptomatic patients, in agreement with current practice. 15 In addition, we routinely stop the administration of NSAIDS five days before surgery since they may increase peri-operative blood loss and transfusion requirements. 16 We have reported a transfusion rate of less than 20% for all patients who have undergone lower-limb arthroplasty in our hospital. 17 The remaining asymptomatic patients had previously been treated with ferrous sulphate (200 mg three times daily) which is a recognised oral treatment for iron-deficiency anaemia. 12 The trauma of surgery affects post-operative erythropoesis. 10, 11 Interleukins, tumour-necrosis factor and endotoxins released after elective hip surgery affect iron metabolism for at least two weeks. 10, 11 There is a decrease in the level of serum iron and transferrin and transferrin saturation and an increase in the level of serum ferritin similar to that seen in the anaemia of chronic disorders, indicating a functional iron deficiency. 10, 11 Uncomplicated iron deficiency results in low levels of serum ferritin and iron and an increased level of serum transferrin but reduced transferrin saturation. This initial inflammatory reaction negates the effect of early oral iron supplementation but may protect against micro-organisms. 10 The inflammatory response persists until approximately four weeks after surgery on the hip when increased levels of serum iron and increased transferrin concentrations indicate the availability of body iron stores.
11
Patients who receive NSAIDs pre-operatively appear to have an increased blood loss after elective hip surgery. 17 Theoretically, NSAIDs may reduce the effects of the postoperative inflammatory response on iron metabolism. Patients who take these preparations may therefore benefit from iron supplementation. However, it has been shown that pathways which involve prostaglandin synthesis may play only a minor role in eliciting this inflammatory response, and therefore the post-operative administration of NSAIDs is unlikely to modify this. 18 Iron balance is maintained by regulating the absorption of dietary iron.
14 This decreases once body iron stores are replete. The decreased intestinal absorption observed in patients with anaemia of chronic disorders may add to the inactivity of oral iron for the correction of anaemia after elective lower-limb surgery. 10 In our experience an increased erythropoetic response persists until at least three weeks after surgery. We observed a significantly raised reticulocyte count on the fifth day and at three weeks, indicating increased erythropoetic stimulation. This had returned to normal by six weeks. This effect was previously reported by Biesma et al, 10 but is negated by the inflammatory response previously discussed.
We indirectly assessed the body iron content from the level of serum ferritin since this is directly related to the available iron storage. 13 Of our patients, 16 of 334 (4.8%) had a low serum ferritin, indicating an iron-deficiency anaemia. Iron supplementation has already been shown to be of value pre-operatively in such patients. They may also benefit from post-operative iron supplementation. 19 Previous studies have had methodological flaws and make statistical conclusions doubtful. We consider that the study by Crosby et al 12 was limited since the number of patients in each group was small, the use of aspirin and reinfused blood was not controlled and some (3%) of the late-visit data were not measured under identical conditions. We also feel that the study by Zauber et al 13 was flawed because no placebo had been used, only small numbers were involved and meaningful data were collected for only the first two weeks. This time interval was not long enough to answer the question as to whether or not a normal diet and increased absorption of iron were sufficient to raise the level of haemoglobin to its normal value more rapidly than a diet containing iron supplements. We have attempted to address these factors.
A large number of patients were unwilling to take part in our study. This group had normal biochemical data before their exclusion and physiologically there was no reason to suggest that exclusion would cause a statistical bias. As a group they may have been less compliant with their medication although we did not measure that. Our study showed that the level of haemoglobin recovered to 85% of its pre-operative value three weeks after surgery, irrespective of iron supplementation. Three weeks later, the patients who had been given ferrous sulphate had a significantly greater increase in recovery. The clinical significance of this additional 3% to 3.5% when compared with the placebo group is unclear but is probably low since all patients had reached recovery of at least 88% of their pre-operative haemoglobin by six weeks.
The benefits of iron supplementation need to be weighed against the potential side-effects reported in up to 25% of patients, which include nausea, vomiting, constipation, diarrhoea and heartburn. 9 We had 12 patients (10%) who were non-compliant because of gastrointestinal side effects. Of these seven were taking placebo. Analgesics taken postoperatively, such as codeine phosphate or NSAIDs, have similar gastrointestinal side effects. It is difficult to establish whether these effects are attributable solely to the iron or to the analgesics. We are unaware of any objective, validated scoring system which can measure the side effects of analgesic medication after lower-limb arthroplasty and, in any event, these symptoms were not recorded.
We, therefore, conclude from the previously reported effects of surgery on iron metabolism and the results of our study that the routine use of ferrous sulphate after total hip and knee arthroplasty is not required.
